Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
Clinical Trials
Overview
Luxeptinib for CLL & NHL
Luxeptinib for AML
Tuspetinib for AML
Expanded Access
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Join Us
Values & Culture
Perks & Benefits
Explore Careers
Contact
Posters & Presentations
Product Pipeline
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
All
Poster
Presentation
October 29, 2023
Poster
2023 ESH Poster – Tuspetinib Oral Myeloid Kinase Inhibitor Creates Synthetic Lethal Vulnerability to Venetoclax
2023 ESH Poster – Tuspetinib Oral Myeloid Kinase Inhibitor Creates Synthetic Lethal Vulnerability to Venetoclax :
View Poster
October 29, 2023
Poster
2023 ESH Poster – Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy as Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
2023 ESH Poster – Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy as Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) :
View Poster
December 11, 2022
Poster
2022 ASH Poster - A Phase 1/2 Open-label, Multicenter, Dose Escalation and Expansion Study of the Myeloid Kinase Inhibitor HM43239 (Tuspetinib) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2022 ASH Poster - A Phase 1/2 Open-label, Multicenter, Dose Escalation and Expansion Study of the Myeloid Kinase Inhibitor HM43239 (Tuspetinib) in Patients with Relapsed or Refractory Acute Myeloid Leukemia:
View Poster
December 11, 2022
Poster
2022 ASH Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-cell Malignancies
2022 ASH Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-cell Malignancies:
View Poster
December 11, 2022
Poster
2022 ASH Poster - A Phase 1 a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes
2022 ASH Poster - A Phase 1 a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes:
View Poster
June 10, 2022
Poster
2022 EHA Poster - Myeloid Kinome Inhibitor HM43239 Overcomes Acquired Resistance in Acute Myeloid Leukemia Models
2022 EHA Poster - Myeloid Kinome Inhibitor HM43239 Overcomes Acquired Resistance in Acute Myeloid Leukemia Models:
View Poster
December 13, 2021
Poster
2021 ASH Poster - A Phase 1a/b Study of APTO-253 in R/R AML and HR-MDS
2021 ASH Poster - A Phase 1a/b Study of APTO-253 in R/R AML and HR-MDS:
View Poster
December 11, 2021
Poster
2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML
2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML:
View Poster
December 11, 2021
Poster
2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R B-Cell Malignancies
2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R B-Cell Malignancies:
View Poster
1
2
3
4
5
Next